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Distal hereditary motor neuropathies (dHMN) are a group of rare hereditary
neuromuscular disorders characterized by an atrophy that affects peroneal muscles in
the absence of sensory symptoms. To date, 23 genes are thought to be responsible for
dHMN, four of which encode chaperones: DNAJB2, which encodes a member of the
HSP40/DNAJ co-chaperone family; and HSPB1, HSPB3, and HSPB8, encoding three
members of the small heat shock protein family. While around 30 different mutations
in HSPB1 have been identified, the remaining three genes are altered in many fewer
cases. Indeed, a mutation of HSPB3 has only been described in one case, whereas
a few cases have been reported carrying mutations in DNAJB2 and HSPB8, most
of them caused by a founder c.352+1G>A mutation in DNAJB2 and by mutations
affecting the K141 residue in the HSPB8 chaperone. Hence, their rare occurrence makes
it difficult to understand the pathological mechanisms driven by such mutations in this
neuropathy. Chaperones can assemble into multi-chaperone complexes that form an
integrated chaperone network within the cell. Such complexes fulfill relevant roles in
a variety of processes, such as the correct folding of newly synthesized proteins, in
which chaperones escort them to precise cellular locations, and as a response to protein
misfolding, which includes the degradation of proteins that fail to refold properly. Despite
this range of functions, mutations in some of these chaperones lead to diseases with a
similar clinical profile, suggesting common pathways. This review provides an overview
of the genetics of those dHMNs that share a common disease mechanism and that are
caused by mutations in four genes encoding chaperones: DNAJB2, HSPB1, HSPB3,
and HSPB8.
Keywords: Distal hereditary motor neuropathy, distal spinal muscular atrophy, DNAJB2, HSPB1, HSPB3,
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CHAPERONES AND CHAPERONOPATHIES
Chaperones (Hartl et al., 2011; Smith et al., 2015) are proteins that, together with the protein
degradation machinery (proteasomes, macroautophagy, etc.), contribute to the quality control
apparatus and to the proteostasis of a cell. Typically, chaperones recognize other proteins (usually
called their clients) to assist in their folding so that they attain their functional conformation
at the sites where they must act. Most chaperones are promiscuous and they bind to many
clients, although others (dedicated chaperones) restrict their associations to one or a few proteins.
However, the information available on the molecules that interact with specific chaperones is still
incomplete.
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Chaperones also participate in other important processes,
such as: (i) the reversion of erroneous folding of newly
synthesized proteins; (ii) the prevention of the formation
of improper protein aggregates and their disassembly; (iii)
the escorting of proteins to their functional sites, including
translocation across membranes and the assembly of functional
protein-protein, protein-DNA or protein-RNA complexes; and
(iv) the sequestering of proteins that are damaged or unable
to fold properly to the intracellular protein degradation
machinery for destruction. Most of these processes require
energy and, therefore, some chaperones have ATP-binding sites
and ATPase activity (e.g., Hsp90, Hsp70). By contrast, ATP-
independent chaperones must cooperate with the former to
carry out such functions. In fact, chaperones tend to assemble
into synergistic multi-chaperone complexes of distinct sizes,
containing chaperones from the same or different families, as
well as other proteins that assist them in their functions, thereby
forming an integrated chaperone network in the cell.
Chaperones can either be constitutively expressed, induced
by stress (usually but not exclusively, heat shock) or both.
Most chaperones induced by heat shock are frequently called
heat shock proteins (HSPs). Chaperones, including HSPs, are
sometimes classified into six major families according to their
molecular mass, although a gross distinction is made between
the larger (e.g., the Hsp100, Hsp90, Hsp70, Hsp60, and Hsp40
co-chaperones) and smaller (sHsp, 12–43 kDa, although the
vast majority are 30 kDa or less) chaperones. Each group
comprises various chaperones and in the human genome, for
example, 10 different chaperones have been identified in the sHsp
family (HspB1-HspB10). Thus, and although the total number
of chaperones in humans is still expanding, an up to date and
conservative estimate of their total number would be about
100 genes (Kakkar et al., 2014). Of course, these genes give
rise to a much larger number of proteins due to the different
transcriptional, translational and post-translational events and
modifications they are subjected to. Given the range of activities
undertaken by chaperones and the vast number of multimeric
complexes that they formwith other chaperones, some functional
redundancies are likely to exist in their extended networks.
Therefore, a single chaperone, or even of a group of dedicated
chaperones, would not be expected to be exclusively responsible
for a specific task with a particular client, and defects in one
chaperone can usually be compensated by others, albeit more or
less successfully. Together with the possible lethality associated
with the loss of some important chaperones, this redundancy
might explain the relatively low number of diseases known to be
produced by mutations in genes encoding chaperones (Macario
and Conway de Macario, 2007; Kakkar et al., 2014).
PROTEOPATHIES AND
CHAPERONOPATHIES
There are many disorders, some that are well known, in which
specific misfolded proteins aggregate and accumulate in cells
(Walker et al., 2006). Classical examples are Huntington’s,
Parkinson’s and Alzheimer’s diseases, although they are not
primarily due to defects in the machinery that assist proteins
to fold properly but rather, to defects in the specific proteins
that accumulate in each disease (e.g., huntingtin, alpha-synuclein,
amyloid-beta peptide, and tau). Therefore, these diseases can be
referred to as proteopathies or proteinopathies and in principle,
they are not considered to be chaperonopathies.
Nevertheless, genetic or post-transcriptional defects in
chaperones may be pathological given their role in protein
folding. In fact, and despite the potential functional redundancy
of chaperones, mutations in genes encoding these proteins have
been associated with various disorders that can be collectively
referred to as chaperonopathies (Macario and Conway de
Macario, 2007). These mutations can affect different yet
important domains of a chaperone (e.g., the ATP binding site,
client recognition site, sites for interaction with other chaperones,
etc.), but they can also affect other sites regulating the expression
or the activity of the chaperone. The role of chaperones implies
that chaperonopathies may be associated with the aggregation of
misfolded proteins but, as mentioned above, such diseases differ
from proteinopathies with respect to the protein that is altered
(either chaperones or other proteins).
THE GROWING LIST OF CHAPERONES
INVOLVED IN DISTAL HEREDITARY
MOTOR NEUROPATHIES
Distal hereditary motor neuropathies (dHMN) or distal spinal
muscular atrophies (dSMA) are a group of rare hereditary
neuromuscular disorders characterized by an atrophy that affects
peroneal muscles in the absence of sensory symptoms (Harding,
1993). Classically, patients experience progressive distal weakness
and atrophy affecting the lower limbs, which subsequently
spreads to the proximal muscles and ultimately reaches the upper
limbs as the disease progresses, with the possible appearance
of foot deformities. Other additional manifestations include
ataxia or pyramidal tract signs, although these are unusual.
These symptoms contrast with those of Charcot-Marie-Tooth
disease (CMT) or hereditarymotor sensory neuropathy (HMSN),
conditions in which sensory involvement is also evident.
However, there are some forms of CMT, in particular in axonal
CMT or CMT type 2 (CMT2), in which only minor sensory
involvement is recognized, and it is difficult to distinguish dHMN
from CMT2 (Harding and Thomas, 1980). In fact, some genetic
overlap is observed in CMT and dHMN as both conditions can
be caused by mutations in the same gene, and even by the same
mutation.
To date 23 genes associated with dHMN have
been reported (Neuromuscular Disease Center,
http://neuromuscular.wustl.edu/synmot.html), although no
molecular diagnosis is available in most dHMN patients (Rossor
et al., 2012a). Distinct activities are affected in motor-nerve
disease, including: protein folding/misfolding (HSPB1, HSPB3,
HSPB8, DNAJB2, and BSCL2), RNA metabolism (IGHMBP2,
SETX, and GARS), axonal transport (DYNC1H1, DCTN1),
cation channel activity (ATP7A, TRPV4), transcriptional control
(FBXO38), etc. Here we will focus exclusively on dHMNs that
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involve mutations in the chaperone genes HSPB1, HSPB8,
DNAJB2, and HSPB3, all four encoding ATP-independent
chaperones. Although, compensatory mechanisms driven by
the relationships and redundancies within the chaperome can
overcome specific chaperone defects, this does not appear to
be the case here, as in other diseases. Indeed, even when this
compensation occurs, the chaperone activity associated to the
defective chaperones would be modified considerably.
The DNAJB2/HSJ1 gene is a member of the HSP40/DNAJ co-
chaperone family, characterized by a highly conserved domain
of about 70 amino acids, the J domain. This domain allows
proteins of this family to interact with Hsp70, and to regulate
its ATPase-dependent activity in protein folding and in protein
complex dissociation (Hageman et al., 2010). Moreover, spliced
transcript variants have been described for theDNAJB2 gene that
encode different isoforms, one of which, DNAJB2a, participates
in the resolution of protein aggregates associated with important
neurodegenerative diseases (Chen et al., 2016 and references
cited therein). Although this protein is mainly expressed in the
brain, it has also been localized in normal and diseased skeletal
muscle, where it is thought to influence protein turnover through
the ubiquitin-proteasome pathway (Claeys et al., 2010). DNAJB2
interacts with ubiquitin chains and their fusion proteins, and
since the proteasome mediates the degradation of selected
proteins, it is possible that some of these proteins are related
to the cytoskeleton (microtubules, intermediate filaments, and
microfilaments), in accordance with the role of the other
chaperones involved in dHMN (see below).
There are 10 cases where autosomal recessive inheritance has
been associated to mutations in the DNAJB2 gene (Table 1).
The first mutation was reported in homozygosis, DNAJB2
c.352+1G>A, and it was identified in a Moroccan family with a
dHMN phenotype (dHMN5) by genome wide mapping (Blumen
et al., 2012). In this case, the expression of DNAJB2 was
dampened in fibroblasts from the patients and overexpression
of the protein reduced the formation of inclusions in a
neuronal cellular model, suggesting DNAJB2 is active in motor
neurons and/or muscle (Blumen et al., 2012). Two additional
homozygous mutations were later described in the DNAJB2
gene, c.229+1G>A and c.14A>G (p.Y5C), in a family diagnosed
with dHMN (dHMN5) and another with CMT2 (CMT2T),
respectively (Gess et al., 2014). More recently, a homozygous
large deletion was reported in a family with spinal muscular
atrophy and parkinsonism, broadening the clinical spectrum of
DNAJB2 related neuropathies (Sanchez et al., 2016).
To date, the remaining known patients with mutations in the
DNAJB2 gene carry the c.352+1G>A mutation in homozygosis:
5 families from Spain (Frasquet et al., 2016; Lupo et al., 2016)
and one from Brazil (Teive et al., 2015). These Spanish families
were investigated by haplotype analysis and they carried the
same homozygous haplotype. Hence, the DNAJB2 c.352+1G>A
mutation appears to be a founder event (Lupo et al., 2016), and
it is shared with a family reported elsewhere (Blumen et al.,
2012). The patients in Spain displayed a dHMN or CMT2
phenotype and, in some cases, initial clinical manifestations
that were consistent with dHMN and that subsequently evolved
to CMT2 (Frasquet et al., 2016). Moreover, the peripheral
motor neuropathy recently described in a Brazilian family
carrying the DNAJB2 c.352+1G>A mutation was associated
with parkinsonism and cerebellar ataxia (Teive et al., 2015).
Some patients show parkinsonian symptoms (Frasquet et al.,
2016; Sanchez et al., 2016; Teive et al., 2015), which probably
are due to the DNAJB2 mutations. Other additional symptoms
such as cerebellar ataxia may be coincidental. Further studies
of a larger analytical series will be necessary to define the
clinical manifestations associated with DNAJB2 mutations in
more depth.
HSPB1, HSPB3, and HSPB8 are the three other chaperones
associated with dHMNs, and they are all members of the sHsp
family. These proteins are characterized by a highly conserved α-
crystallin domain that is related to their chaperone activity, which
is more closely associated with an 80–100 amino acid domain in
the C- rather than theN-terminal region of the protein (Nefedova
et al., 2015). These chaperones are normally found as monomers,
but under stress, they tend to also interact with each other to
form large, labile homo- and hetero-oligomeric complexes of
more than twenty identical or different subunits, driving their
recognition and interaction with new protein clients (Arrigo,
2013). Certain sHsp are tissue specific, while others are more
ubiquitously expressed in function of the tissue and conditions.
The main role of sHsps is to carry their denatured clients to ATP-
dependent chaperones for renaturation or to the cell’s protein
degradation machinery (proteasomes and autophagosomes). In
terms of dHMN and HMSN, sHsps stabilize the activities of
the cell cytoskeleton, interacting with most of its proteins
components, as well as preventing oxidative stress (Nefedova
et al., 2015).
Autosomal dominant mutations in the HSPB1/HSP27 gene
were first described in four families with dHMN (dHMN2B) and
in one family with CMT2 (CMT2F) (Evgrafov et al., 2004). More
than 30 different mutations causing dHMN or CMT2 have since
been described in the HSPB1 gene, some of which also produce
other manifestations (Table 1; Evgrafov et al., 2004; Kijima et al.,
2005; Tang B. et al., 2005; Chung et al., 2008; Houlden et al.,
2008; James et al., 2008; Ikeda et al., 2009; Luigetti et al., 2010;
Mandich et al., 2010; Solla et al., 2010; Murphy et al., 2012;
Rossor et al., 2012b; Sivera et al., 2013; Ylikallio et al., 2014,
2015). An autosomal recessive mutation in the HSPB1 gene was
identified in a consanguineous family with a similar clinical
profile (Houlden et al., 2008). On the whole, HSPB1 mutations
are inherited dominantly and while most involve a change in
one codon, they may also produce a frameshift or premature
stop codons. The protein encoded by this gene is ubiquitously
expressed and it is induced by environmental stress, translocating
from the cytoplasm to the nucleus to influence stress resistance
and produce other changes. The known mutations are located in
all three domains of the protein: N-terminus, α-crystallin and C-
terminus. These HSPB1mutations mostly modify the oligomeric
state of the protein, usually negatively but also positively (certain
mutations in the α-crystallin domain), altering its chaperone
activity and in both cases affecting normal cytoskeletal function.
HSPB1 is involved in the organization of the neurofilament
network, which is important to maintain the axonal cytoskeleton
and transport, and indeed, overexpression of HSPB1 mutants
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TABLE 1 | Mutations reported in DNAJB2, HSPB1, HSPB3 and HSPB8 involved in hereditary neuropathies.
Gene HGVS (nucleotide) HGVS (protein) Disease/Phenotype References
DNAJB2 c.352+1G>A donor site dHMN/CMT2 Blumen et al., 2012; Frasquet et al., 2016; Lupo et al., 2016
c.229+1G>A donor site dHMN Gess et al., 2014
c.14A>G p.Y5C dHMN Gess et al., 2014
HSPB1 c.20C>G p.P7R CMT2 Luigetti et al., 2010
c.45C>A p.S15R Peripheral neuropathy Antoniadi et al., 2015
c.100G>A p.G34R HMSN Capponi et al., 2011; Muranova et al., 2015
c.116C>T p.P39L dHMN/CMT2 Houlden et al., 2008; Muranova et al., 2015; Yavarna et al., 2015
c.121G>A p.E41K dHMN Capponi et al., 2011; Muranova et al., 2015
c.250G>A p.G84R CMT2 Manganelli et al., 2014
c.250G>C p.G84R dHMN James et al., 2008; Fischer et al., 2012; Nefedova et al., 2015
c.257C>T p.S86L dHMN/ALS Scarlato et al., 2015
c.295C>A p.L99M dHMN/CMT2 Houlden et al., 2008; Nefedova et al., 2015
c.380G>T p.R127L CMT2 Hoyer et al., 2014; Ylikallio et al., 2015
c.379C>T p.R127W dHMN Evgrafov et al., 2004; Almeida-Souza et al., 2011
c.404C>G p.S135C CMT2 Benedetti et al., 2010; Oberstadt et al., 2016
c.404C>G p.S135C CMT2 Benedetti et al., 2010; Oberstadt et al., 2016
c.404C>T p.S135F CMT2 Evgrafov et al., 2004; Almeida-Souza et al., 2010, 2011
c.404C>A p.S135Y CMT2 Ylikallio et al., 2014
c.407G>T p.R136L dHMN/CMT2 Capponi et al., 2011; Gaeta et al., 2012; Stancanelli et al., 2015
c.406C>T p.R136W CMT2 Evgrafov et al., 2004; Almeida-Souza et al., 2010, 2011
c.418C>G p.R140G dHMN/CMT2 Houlden et al., 2008; Nefedova et al., 2015
c.421A>C p.K141Q dHMN Ikeda et al., 2009; Nefedova et al., 2013; Maeda et al., 2014
c.452C>T p.T151I dHMN Evgrafov et al., 2004; Almeida-Souza et al., 2010, 2011
c.490A>G p.T164A CMT2 Lin et al., 2011
c.523C>T p.Q175X CMT2 Rossor et al., 2012b
c.539C>T p.T180I dHMN/CMT2 Luigetti et al., 2010
c.545C>T p.P182L dHMN Evgrafov et al., 2004; Almeida-Souza et al., 2010, 2011
c.544C>T p.P182S dHMN Kijima et al., 2005
c.562C>T p.R188W CMT2 Capponi et al., 2011
c.365-13C>T acceptor site CMT2 Benedetti et al., 2010
c.-217T>C regulatory ALS Dierick et al., 2007
c.476_477delCT p.P159RfsX41 Peripheral neuropathy, early onset Mandich et al., 2010; Capponi et al., 2011
c.505delA p.M169CfsX4 CMT DiVincenzo et al., 2014
c.171_172insGCGCCCT p.L58AfsX105 CMT DiVincenzo et al., 2014
HSPB3 c.21G>T p.R7S dHMN Kolb et al., 2010
HSPB8 c.423G>C) p.L141N dHMN/CMT2 Irobi et al., 2004
c.421A>G p.L141E dHMN Irobi et al., 2004
c.423G>T p.L141N CMT2 Tang B. S. et al., 2005
c.422A>C p.L141T CMT2 Nakhro et al., 2013
c.151insC p.P173SfsX43 Distal myopathy/dHMN Ghaoui et al., 2016
ALS, Amyotrophic lateral sclerosis; CMT2, Charcot-Marie-Tooth disease type 2 or axonal; dHMN, Distal hereditary motor neuropathy; HMSN, hereditary motor and sensory neuropathy.
produces protein aggregates and altered neurofilament transport
in the axon (Evgrafov et al., 2004; Ackerley et al., 2006; Zhai
et al., 2007). Thus, an increased interaction with tubulin and an
enhanced stability of the microtubule network has been observed
for some mutants (Almeida-Souza et al., 2011). Moreover, there
are severe defects in axon transport in transgenic mice expressing
human mutant HSPB1 in neurons due to a decrease in acetylated
α-tubulin (d’Ydewalle et al., 2011). As a result, inhibitors of
histone deacetylase 6 (HDAC6, a client of HSPB1 that acetylates
α-tubulin) have successfully reversed the axonal loss in a mouse
model of CMT2F that expresses mutant HSPB1 (d’Ydewalle et al.,
2011). HSPB1 is also involved in a variety of human diseases,
such as cancer, Alzheimer’s disease and heart disease (Sun and
MacRae, 2005).
At present, only one family is thought to carry clinical
mutations in the HSPB3/HSPL27 gene: a missense mutation
c.21G>T (p.R7S) described in two affected sisters who suffer
from dHMN (dHMN2C) (Table 1; Kolb et al., 2010). The
function of HSPB3 is not fully understood, although replacing
the positively charged R7 residue with a neutral polar amino acid
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would affect its structure and therefore, its proprieties. In contrast
to the ubiquitous expression of HSPB1 and HSPB8, HSPB3 is
more tissue specific (heart, brain, skeletal and smooth muscle)
and it is expressed strongly in muscle (Sugiyama et al., 2000).
HSPB3 interacts with HSPB2 and these two proteins in turn
both interact with HSPB8, potentially contributing to maintain
myofibril integrity (Fontaine et al., 2005). Finally, HSPB3 and
HSPB2 are upregulated in a mouse model for spinal and bulbar
muscular atrophy (SBMA), an inherited motoneuron disease
(Rusmini et al., 2015).
Mutations in the HSPB8/HSP22 gene were first associated
with dHMN (dHMN2A) (Irobi et al., 2004) and later, with
CMT2 (CMT2L) (Table 1; Tang B. S. et al., 2005). Four
mutations have been described and they all affect position
K141: c.423G>T/c.423G>C (p.K141N), c.421A>G (p.K141E),
and c.422A>C (p.K141T). These mutations are all transmitted
in an autosomal dominant fashion (Irobi et al., 2004; Tang B.
S. et al., 2005; Nakhro et al., 2013), and this hot-spot residue
is located in a hydrophobic strand of the α-crystallin domain.
The mutations eliminate the positive charge of the K41 amino
acid, which will affect the interactions of HSPB8 with other
sHsps like HSPB27, HSPB3, and HSPB2 (Irobi et al., 2004;
Fontaine et al., 2006; Kasakov et al., 2007; Nakhro et al., 2013).
Mutational screening in a large clinical series revealed additional
patients but no novel mutations associated with dHMN or CMT2
(Dierick et al., 2008; Sivera et al., 2013; Fridman et al., 2015).
However, two mutations, c.421A>G (p.K141E), and c.151insC
(p.P173SfsX43) were recently described in two unrelated families
with a new distal neuromyopathy phenotype, expanding the
clinical phenotype associated with HSPB8 (Ghaoui et al., 2016).
HSPB8 is ubiquitously expressed (particularly strongly in the
spinal cord, and especially in motor and sensory neurons), and
it acts as a chaperone and a regulator of apoptosis (Shemetov
et al., 2008). HspB8 acts as a chaperone in association with
the co-chaperones Bag3 and Stub1, stimulating chaperone-
assisted selectivemacroautophagy inmuscle tomaintain the actin
cytoskeleton (Arndt et al., 2010). Expression of HSPB8 mutants
in cell models promotes the formation of intracellular aggregates
and it augments cell death (Benn et al., 2002; Irobi et al., 2004).
These protein aggregates are also observed in fibroblasts from
patients who carry HSPB8 mutations, and they are coupled to a
decrease in mitochondrial membrane potential and a reduction
in cell viability (Irobi et al., 2012; Vicario et al., 2014). Although
the pathological mechanisms underlying these conditions remain
enigmatic, specific motor neuron degeneration is associated with
HSPB8 mutations (Irobi et al., 2010). In addition, expression of
this protein can be induced by estrogen in estrogen receptor-
positive breast cancer cells, indicating a role in carcinogenesis,
and suggesting the possible involvement of HspB8 in regulating
cell proliferation and apoptosis.
Since mutations in these four chaperones, as well as those in
other genes, produce a similar pathological phenotype, it would
seem obvious that they must share some pathogenic pathways. It
has been proposed that most, if not all, of the proteins affected
in dHMN/CMT2 are related with the impaired axonal trafficking
of cell components (Bucci et al., 2012; Gentil and Cooper, 2012).
Considering the activity of all the chaperones described above,
it appears that mutations in all these genes could affect the
cytoskeleton, either by interacting with relevant proteins (e.g., in
the case of the sHsps) or by regulating their specific degradation
(e.g., in the case of DNAJB2 and HspB8). Since the cytoskeleton
participates in axonal transport, as well as in the dynamics of
various organelles and plasma membrane receptors, there are
clear potential relationships with other mutations that cause
dHMN/CMT2. To date there are no effective treatments for
these diseases and therefore, much more research is needed
to understand the consequences of each specific mutation
that provokes them. However, one potential therapy to be
considered, at least in certain cases of these chaperonopathies,
could be to overexpress the chaperone to rescue its defective
functions. Indeed, the overexpression of HspB8 ameliorates the
accumulation of aggregates associated with the p.P182Lmutation
in HspB1 (Carra et al., 2010), or the effects on its clients, as
illustrated by the use of inhibitors of histone deacetylase 6 to treat
CMT2F (d’Ydewalle et al., 2011).
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